| INTRODUCTION
Information on adverse neurocognitive effects due to medical products derived only from adults does not address the potential effects on the developing brains of pediatric patients. This information must be obtained from clinical studies in children. 1 Workshop topics and subtopics are outlined below.
1.1 | What are the major challenges in the evaluation of long-term neurocognitive and behavioral outcomes?
There are many questions at the forefront of evaluating long-term neurocognitive and behavioral outcomes in children exposed to medical products. Do effects of a medication given to children occur soon Anesthetic community aims to further understand the potential risks of anesthetic agents on the developing brain.
Published 2017. This article is a U.S. Government work and is in the public domain in the USA 3. The choice of neurocognitive testing measures for a specific study may be guided by the characteristics of the pediatric population at risk, the disorder under treatment, and/or the specific drug under study. In addition, encouraging the use of some standardized neurocognitive assessments in most studies could make crossstudy comparisons among different drug therapies more informative.
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